Business Context and Reporting Period
Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004
Business Overview: The Company operates in the direct sales industry, marketing health and wellness products through independent Distributors and Managers. Operations are divided into five segments: United States, Latin America, Asia Pacific, Other International, and Synergy Worldwide.
Key Financial Metrics
| Metric (in thousands) | Q1 2004 | Q1 2003 |
|---|---|---|
| Net Sales Revenue | $76,896 | $62,663 |
| Operating Income | $3,604 | $2,215 |
| Net Income | $2,988 | $1,604 |
| Diluted EPS | $0.20 | $0.11 |
| Cash Flow from Operations | $8,976 | $5,329 |
| Cash and Equivalents (Ending) | $35,196 | $23,683 |
| Line of Credit Outstanding | $0 | $5,000 |
Margins: Operating margin improved to 4.7% in Q1 2004 from 3.5% in Q1 2003. Net income margin was 3.9% compared to 2.6% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22.7% year-over-year, driven primarily by the Synergy Worldwide segment (up from $1.6M to $13.2M) and international operations in Latin America and "Other" markets.
- Segment Performance:
- United States: Sales decreased 2.8% to $36.0M.
- Asia Pacific: Sales decreased 29.6% to $3.4M due to competition in South Korea.
- Latin America: Sales increased 19.0% to $14.0M.
- Profitability: Net income increased 86.3% to $2.99M. Operating expenses as a percentage of sales decreased to 95.3% from 96.5%.
- Liquidity: Cash and cash equivalents increased by $4.5M to $35.2M. The Company repaid $5.0M on its line of credit, leaving no outstanding balance.
- Accounting Reclassification: The Company reclassified volume incentive rebates as a reduction of sales revenue rather than an operating expense (per EITF 01-9). This affected reported revenue and expense figures but had no impact on operating income or net income.
Outlook, Risks, and Management Commentary
- Guidance: Management expects cost of goods sold to decrease slightly as a percentage of sales for the remainder of 2004 due to a U.S. price increase effective April 1, 2004, and currency stabilization. SG&A expenses as a percentage of sales are expected to decrease due to cost controls.
- Product Liability Risk: The Company faces inherent risks regarding product liability claims. It could not obtain insurance for products containing ephedrine alkaloids and kava but complied with the FDA ban on ephedra effective April 12, 2004. The Company self-insures for certain liabilities and maintains a captive insurance company.
- Market Risk: Approximately 38.4% of revenue is realized outside the U.S. Results are sensitive to foreign currency fluctuations; a weakening U.S. dollar generally benefits operating results. The Company does not use derivative instruments for hedging.
- Capital Resources: The Company has a $15M unsecured line of credit maturing July 1, 2004. It currently has no borrowings and is in compliance with all covenants.
Investor Verification Checklist
- Synergy Worldwide Sustainability: Verify the sustainability of the massive revenue jump in the Synergy Worldwide segment ($1.6M to $13.2M) and its impact on future volume incentive costs.
- Asia Pacific Decline: Assess the long-term impact of the 29.6% sales decline in the Asia Pacific region due to competition in South Korea.
- Product Liability Exposure: Review the adequacy of the self-insurance accruals for product liability claims, particularly given the inability to insure ephedra/kava products prior to the ban.
- Foreign Currency Sensitivity: Monitor exchange rate trends for key markets (Mexico, Venezuela, South Korea) as 38.4% of revenue is foreign-sourced.
- Volume Incentive Structure: Confirm that the reclassification of rebates to revenue reduction does not obscure the true cost structure of the direct sales model.